Skip to main content
SpringerLink
Log in

Drug Treatment of Raynaud’s Phenomenon

  • Chapter
  • First Online:
Raynaud’s Phenomenon

  • 1699 Accesses

Abstract

Sometimes Raynaud’s Phenomenon (RP) is symptomatic enough to warrant pharmacological treatment. The principles of RP treatment are to decrease the frequency of attacks, lessen the duration of attacks, and to prevent or treat complications especially after failure of conservative treatment (staying warm, avoiding stress and other precipitators, and smoking cessation). In general secondary RP is more severe than primary and the majority of patients with both primary and secondary RP do not require drug treatment. However, the most severe RP patients are often those with arterial occlusion/obliteration such as those with systemic sclerosis associated RP. First line drug treatment is initiation of dihydropyridine class of calcium channel blockers (CCBs), where the most studied is nifedipine. Achievable goals of treatment with CCBs may be a 1/3 reduction in frequency of attacks. Other CCBs could be considered such as amlodipine, felodipine, and nicardipine. If this class is not effective or not tolerated (due to side effects such as hypotension and peripheral edema), then in moderate to severe secondary RP, PDE5 inhibitors are considered and or prostacyclins such as intravenous iloprost. In mild RP, PDE5 inhibitors or losarten (an angiotension II inhibitor) or fluoxetine (a selective serotonin reuptake inhibitor) may be considered with some positive randomized controlled trial data. Topical nitrates may be helpful, but there can be dose dependent side effects such as headache and hypotension. Angiotensin-converting-enzyme inhibitors have mostly negative data. Trends in treatment of uncomplicated moderate to severe RP are using combinations of drugs if tolerated and after obtaining a partial response with CCBs such as adding PDE5 inhibitors. Complications of secondary RP (both prevention and treatment) are discussed in Chap. 19.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACE:

Angiotensin-converting enzyme

AEs:

Adverse events

CAMs:

Complementary and alternative medicine

CCBs:

Calcium channel blockers

CGRP:

Calcitonin gene related peptide

CTD:

Clinical trial data

EULAR:

European league against rheumatism

EUSTAR:

EULAR scleroderma trials and research

5HT:

5-Hydroxytryptamine

MCTD:

Mixed connective tissue disease

NO:

Nitric oxide

PAD:

Peripheral vascular disease

PDE5:

Phosphodiesterase 5

RCS:

Raynaud’s condition score

RCTs:

Randomized clinical trials

RP:

Raynaud’s phenomenon

SCTC:

Scleroderma clinical trials consortium

SERM:

Selective estrogen receptor modulator

SSc:

Scleroderma

SSRI:

Selective serotonin reuptake inhibitors

VAS:

Visual analog scale

WMD:

Weighted mean difference

References

  1. Pope J. Raynaud’s phenomenon (primary). Clin Evid. 2003;9:1339–48.

    PubMed  Google Scholar 

  2. Huisstede BM, Hoogvliet P, Paulis WD, van Middelkoop M, Hausman M, Coert JH, Koes BW. Effectiveness of interventions for secondary Raynaud’s phenomenon: a systematic review. Arch Phys Med Rehabil. 2011;92(7):1166–80. doi:10.1016/j.apmr.2011.01.022.).

    PubMed  Google Scholar 

  3. Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620–8. doi:10.1136/ard.2008.096677. PMID: 19147617.

    PubMed  CAS  Google Scholar 

  4. Walker KM, Pope J, et al. Treatment of systemic sclerosis (SSc) including organ involvement: what to use when firstline treatment fails – a consensus of SSc experts. Semin Arthritis Rheum. 2012;42(1):42–55.

    PubMed  CAS  Google Scholar 

  5. Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud’s phenomenon: a review. Semin Arthritis Rheum. 2012;41:599–603.

    PubMed  CAS  Google Scholar 

  6. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44(8):1841–7.

    PubMed  CAS  Google Scholar 

  7. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology (Oxford). 2005;44(2):145–50.

    CAS  Google Scholar 

  8. Challenor VF, Waller DG, Hayward RA, et al. Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud’s phenomenon. Angiology. 1989;40:122–8.

    PubMed  CAS  Google Scholar 

  9. Gjorup T, Kelbaek H, Hartling OJ, et al. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud’s phenomenon. Am Heart J. 1986;111:742–5.

    PubMed  CAS  Google Scholar 

  10. Ferri C, Cecchetti R, Cini G, Gambini I, La Civita L, Bernini L, Bombardieri S, Pasero G. Slow-releasing nicardipine in the treatment of Raynaud’s phenomena without underlying diseases. Clin Rheumatol. 1992;11(1):76–80.

    PubMed  CAS  Google Scholar 

  11. Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. French Cooperative Multicenter Group for Raynaud Phenomenon, Paris, France. Am Heart J. 1991;122(1 Pt 2):352–5.

    Google Scholar 

  12. Ko GD, Berbrayer D. Effect of ceramic-impregnated “thermoflow” gloves on patients with Raynaud’s syndrome: randomized, placebo-controlled study. Altern Med Rev. 2002;7(4):328–35.

    PubMed  Google Scholar 

  13. Rupp PA, Mellinger S, Kohler J, Dorsey JK, Furst DE. Nicardipine for the treatment of Raynaud’s phenomena: a double blind crossover trial of a new calcium entry blocker. J Rheumatol. 1987;14(4):745–50.

    PubMed  CAS  Google Scholar 

  14. Kahan A, Amor B, Menkès CJ, Weber S, Guérin F, Degeorges M. Nicardipine in the treatment of Raynaud’s phenomenon: a randomized double-blind trial. Angiology. 1987;38(4):333–7. PMID: 3555175.

    PubMed  CAS  Google Scholar 

  15. Wollersheim H, Thien T. Double-blind placebo-controlled crossover study of oral nicardipine in the treatment of Raynaud’s phenomenon. J Cardiovasc Pharmacol. 1991;18(6):813–8. PMID: 1725892.

    PubMed  CAS  Google Scholar 

  16. Wigley FM, Wise RA, Malamet R, Scott TE. Nicardipine in the treatment of Raynaud’s phenomenon. Dissociation of platelet activation from vasospasm. Arthritis Rheum. 1987;30(3):281–6.

    PubMed  CAS  Google Scholar 

  17. La Civita L, Pitaro N, Rossi M, Gambini I, Giuggioli D, Cini G, Ferri C. Amlodipine in the treatment of Raynaud’s phenomenon. Br J Rheumatol. 1993;32(6):524–5.

    PubMed  Google Scholar 

  18. Schmidt JF, Valentin N, Nielsen SL. The clinical effect of felodipine and nifedipine in Raynaud’s phenomenon. Eur J Clin Pharmacol. 1989;37(2):191–2.

    PubMed  CAS  Google Scholar 

  19. Challenor VF, Waller DG, Francis DA, Francis JL, Mani R, Roath S. Nisoldipine in primary Raynaud’s phenomenon. Eur J Clin Pharmacol. 1987;33(1):27–30.

    PubMed  CAS  Google Scholar 

  20. Rhedda A, McCans J, Willan AR, Ford PM. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud’s phenomenon. J Rheumatol. 1985;12(4):724–7.

    PubMed  CAS  Google Scholar 

  21. Kahan A, Amor B, Menkes CJ. A randomised double-blind trial of diltiazem in the treatment of Raynaud’s phenomenon. Ann Rheum Dis. 1985;44(1):30–3.

    PubMed  CAS  PubMed Central  Google Scholar 

  22. Smith CR, Rodeheffer RJ. Treatment of Raynaud’s phenomenon with calcium channel blockers. Am J Med. 1985;78(2B):39–42.

    PubMed  CAS  Google Scholar 

  23. Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72(10):1696–9. doi:10.1136/annrheumdis-2012-202836.

    PubMed  CAS  Google Scholar 

  24. Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation. 2005;112(19):2980–5.

    PubMed  CAS  Google Scholar 

  25. Herrick AL, van den Hoogen F, Gabrielli A, Tamimi N, Reid C, O’Connell D, Vázquez-Abad MD, Denton CP. Modified-release sildenafil reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum. 2011;63(3):775–82. doi:10.1002/art.30195.

    PubMed  CAS  Google Scholar 

  26. Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, Agarwal V. Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 2010;49(12):2420–8.

    CAS  Google Scholar 

  27. Friedman EA, Harris PA, Wood AJ, Stein CM, Kurnik D. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud’s phenomenon. Clin Pharmacol Ther. 2007;81(4):503–9.

    PubMed  CAS  Google Scholar 

  28. Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, Phillips K, Seibold JR. Randomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol. 2009;36(10):2264–8. doi:10.3899/jrheum.090270.

    PubMed  CAS  Google Scholar 

  29. Caglayan E, Axmann S, Hellmich M, Moinzadeh P, Rosenkranz S. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med. 2012;172(15):1182–4. doi:10.1001/archinternmed.2012.2271.

    PubMed  CAS  Google Scholar 

  30. Lee EY, Park JK, Lee W, Kim YK, Park CS, Giles JT, Park JW, Shin K, Lee JS, Song YW, Lee EB. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud’s phenomenon: a double-blind, randomized, cross-over study. Rheumatology. 2014;53(4):658–64.

    PubMed  CAS  Google Scholar 

  31. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012;99(12):1630–8.

    PubMed  CAS  Google Scholar 

  32. Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, Thomas S, Michaels J, Stansby G. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess. 2011;15(40):1–210.

    PubMed  CAS  Google Scholar 

  33. Arosio E, Montesi G, Zannoni M, Paluani F, Lechi A. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud’s phenomenon. Angiology. 1989;40(7):633–8.

    PubMed  CAS  Google Scholar 

  34. Rajagopalan S, Pfenninger D, Somers E, Kehrer C, Chakrabarti A, Mukherjee D, Brook R, Kaplan MJ. Effects of cilostazol in patients with Raynaud’s syndrome. Am J Cardiol. 2003;92(11):1310–5.

    PubMed  CAS  Google Scholar 

  35. Belch JJ, Newman P, Drury JK, McKenzie F, Capell H, Leiberman P, Forbes CD, Prentice CR. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud’s syndrome. A double-blind controlled trial. Lancet. 1983;1(8320):313–5.

    PubMed  CAS  Google Scholar 

  36. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;2, CD000953.

    PubMed  Google Scholar 

  37. Kawald A, Burmester GR, Huscher D, Sunderkötter C, Riemekasten G. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud’s phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol. 2008;35(9):1830–7.

    PubMed  CAS  Google Scholar 

  38. Vayssairat M. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud’s phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. J Rheumatol. 1996;23(11):1917–20.

    PubMed  CAS  Google Scholar 

  39. Shah AA, Schiopu E, Hummers LK, Wade M, Phillips K, Anderson C, et al. Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. Arthritis Res Ther. 2013;15:R54.

    PubMed  Google Scholar 

  40. Seibold JR, Wigley FM, Schiopu E, Denton CD, Silver RM, Steen VD, Medsger Jr TA, Mayes MD, Chatterjee S, Chung L, Csuka ME, Khanna D, Frech TM, Molitor JA, Rothfield NF, Herrick AL, Simms RW, Pope JE, Rollins KD, Arneson C, Wade M, DISTOL Investigators. Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebo-controlled, multicenter study. Arthritis Rheum. 2011;63:S968.

    Google Scholar 

  41. Marasini B, Massarotti M, Bottasso B, Coppola R, Papa ND, Maglione W, Comina DP, Maioli C. Comparison between iloprost and alprostadil in the treatment of Raynaud’s phenomenon. Scand J Rheumatol. 2004;33(4):253–6.

    PubMed  CAS  Google Scholar 

  42. Bartolone S, Trifiletti A, De Nuzzo G, Scamardi R, Larosa D, Sottilotta G, Raffa A, Barbera N. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud’s phenomenon. Minerva Cardioangiol. 1999;47(5):137–43.

    PubMed  CAS  Google Scholar 

  43. Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud’s syndrome. Ann Rheum Dis. 1985;44(11):754–60.

    PubMed  CAS  PubMed Central  Google Scholar 

  44. Belch JJ, Madhok R, Shaw B, Leiberman P, Sturrock RD, Forbes CD. Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, in treatment of Raynaud’s phenomenon. Lancet. 1985;1(8439):1180–3.

    PubMed  CAS  Google Scholar 

  45. Stewart M, Morling JR. Oral vasodilators for primary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2012;7, CD006687. doi:10.1002/14651858.CD006687.pub3.

    PubMed  Google Scholar 

  46. Vinjar B, Stewart M. Oral vasodilators for primary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2008;2, CD006687. doi:10.1002/14651858.CD006687.pub2.

    PubMed  Google Scholar 

  47. Fischer M, Reinhold B, Falck H, Török M, Alexander K. Topical nitroglycerin ointment in Raynaud’s phenomenon. Z Kardiol. 1985;74(5):298–302.

    PubMed  CAS  Google Scholar 

  48. Coppock JS, Hardman JM, Bacon PA, Woods KL, Kendall MJ. Objective relief of vasospasm by glyceryl trinitrate in secondary Raynaud’s phenomenon. Postgrad Med J. 1986;62(723):15–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  49. Tucker AT, Pearson RM, Cooke ED, Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud’s syndrome: a randomised trial. Lancet. 1999;354(9191):1670–5.

    PubMed  CAS  Google Scholar 

  50. Teh LS, Manning J, Moore T, Tully MP, O’Reilly D, Jayson MI. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol. 1995;34(7):636–41.

    PubMed  CAS  Google Scholar 

  51. Nahir AM, Schapira D, Scharf Y. Double-blind randomized trial of nitroderm TTS in the treatment of Raynaud’s phenomenon. Isr J Med Sci. 1986;22(2):139–42.

    PubMed  CAS  Google Scholar 

  52. Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009;60(3):870–7. doi:10.1002/art.24351.

    PubMed  CAS  Google Scholar 

  53. Diehm C, Müller-Bühl U, Mörl H. Isosorbide dinitrate ointment in Raynaud’s disease. Z Kardiol. 1983;72 Suppl 3:185–7.

    PubMed  Google Scholar 

  54. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999;42(12):2646–55.

    PubMed  CAS  Google Scholar 

  55. Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud’s phenomenon. Ann Pharmacother. 2006;40(11):1998–2002.

    PubMed  CAS  Google Scholar 

  56. Rustin MH, Almond NE, Beacham JA, Brooks RJ, Jones DP, Cooke ED, Dowd PM. The effect of captopril on cutaneous blood flow in patients with primary Raynaud’s phenomenon. Br J Dermatol. 1987;117(6):751–8.

    PubMed  CAS  Google Scholar 

  57. Challenor VF, Waller DG, Hayward RA, Griffin MJ, Roath OS. Subjective and objective assessment of enalapril in primary Raynaud’s phenomenon. Br J Clin Pharmacol. 1991;31(4):477–80.

    PubMed  CAS  PubMed Central  Google Scholar 

  58. Janini SD, Scott DG, Coppock JS, Bacon PA, Kendall MJ. Enalapril in Raynaud’s phenomenon. J Clin Pharm Ther. 1988;13(2):145–50.

    PubMed  CAS  Google Scholar 

  59. Gliddon AE, Doré CJ, Black CM, McHugh N, Moots R, Denton CP, Herrick A, Barnes T, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 2007;56(11):3837–46.

    PubMed  CAS  Google Scholar 

  60. Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001;40(9):1038–43.

    CAS  Google Scholar 

  61. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A. Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;2, CD000956.

    PubMed  Google Scholar 

  62. Wollersheim H, Thien T, Fennis J, van Elteren P, van’t Laar A. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon. Clin Pharmacol Ther. 1986;40(2):219–25.

    PubMed  CAS  Google Scholar 

  63. Nielsen SL, Vitting K, Rasmussen K. Prazosin treatment of primary Raynaud’s phenomenon. Eur J Clin Pharmacol. 1983;24(3):421–3.

    PubMed  CAS  Google Scholar 

  64. Le Quentrec P, Lefebvre ML. Double-blind placebo-controlled trial of buflomedil in the treatment of Raynaud’s phenomenon: six-month follow-up. Angiology. 1991;42(4):289–95.

    PubMed  Google Scholar 

  65. Grigg MJ, Nicolaides AN, Papadakis K, Wolfe JH. The efficacy of thymoxamine in primary Raynaud’s phenomenon. Eur J Vasc Surg. 1989;3(4):309–13.

    PubMed  CAS  Google Scholar 

  66. Wesseling H, den Heeten A, Wouda AA. Sublingual and oral isoxsuprine in patients with Raynaud’s phenomenon. Eur J Clin Pharmacol. 1981;20(5):329–33.

    PubMed  CAS  Google Scholar 

  67. van de Wal HJ, Wijn PF, van Lier HJ, Skotnicki SH. The effectiveness of ketanserin in patients with primary Raynaud’s phenomenon. A randomized, double blind, placebo controlled study. Int Angiol. 1987;6(3):313–22.

    PubMed  Google Scholar 

  68. Coffman JD, Clement DL, Creager MA, Dormandy JA, Janssens MM, McKendry RJ, Murray GD, Nielsen SL. International study of ketanserin in Raynaud’s phenomenon. Am J Med. 1989;87(3):264–8.

    PubMed  CAS  Google Scholar 

  69. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A. Ketanserin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;2, CD000954.

    PubMed  Google Scholar 

  70. Kato S, Kishiro I, Ohnuma N, Takasaki K, Okamoto S, Nakamoto T, et al. Suppressive effect of saprogrelate hydrochloride on Raynaud’s phenomenon and respiratory failure in patients with systemic sclerosis. Respirology. 2000;5:27–32.

    PubMed  CAS  Google Scholar 

  71. Bounameaux HM, Hellemans H, Verhaege R. Digital pressure and flow measurement upon local cooling in Raynaud’s disease. Effect of naftidrofuryl. Int Angiol. 1986;5(1):39–44.

    PubMed  CAS  Google Scholar 

  72. Davinroy M, Mosnier M. Double-blind clinical evaluation of naftidrofuryl in Raynaud’s phenomenon. Sem Hop Paris. 1993;69:1322–6 (In French).

    Google Scholar 

  73. Bunker CB, Reavley C, O’Shaughnessy DJ, Dowd PM. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenon. Lancet. 1993;342(8863):80–3.

    PubMed  CAS  Google Scholar 

  74. Shawket S, Dickerson C, Hazleman B, Brown MJ. Prolonged effect of CGRP in Raynaud’s patients: a double-blind randomised comparison with prostacyclin. Br J Clin Pharmacol. 1991;32(2):209–13.

    PubMed  CAS  PubMed Central  Google Scholar 

  75. Whitmore SE, Wigley FM, Wise RA. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud’s phenomenon. J Rheumatol. 1995;22(1):50–4.

    PubMed  CAS  Google Scholar 

  76. Pope JE. Raynaud’s phenomenon (primary). Clin Evid (Online) 2011; pii: 1119.

    Google Scholar 

  77. Sunderland GT, Belch JJF, Sturrock RD, Forbes CD, McKay AJ. A double blind randomised placebo controlled trial of Hexopal in primary Raynaud’s disease. Clin Rheumatol. 1988;7:46–9.

    PubMed  CAS  Google Scholar 

  78. Murphy R. The effect of inositol nicotinate (Hexopal) in patients with Raynaud phenomenon – a placebo-controlled study. Clin Trials J. 1985;22:521–9.

    Google Scholar 

  79. Destors JM, Gauthier E, Lelong S, Boissel JP. Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud’s phenomenon. Angiology. 1986;37(8):565–9.

    PubMed  CAS  Google Scholar 

  80. Rustin MH, Grimes SM, Kovacs IB, Cooke ED, Bowcock SA, Sowemimo-Coker SO, Turner P, Kirby JD. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud’s syndrome. Eur J Clin Pharmacol. 1984;27(1):61–5.

    PubMed  CAS  Google Scholar 

  81. Ettinger WH, Wise RA, Schaffhauser D, Wigley FM. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud’s phenomenon. Am J Med. 1984;77(3):451–6.

    PubMed  CAS  Google Scholar 

  82. Coffman JD, Rasmussen HM. Effect of thromboxane synthetase inhibition in Raynaud’s phenomenon. Clin Pharmacol Ther. 1984;36(3):369–73.

    PubMed  CAS  Google Scholar 

  83. Tindall H, Tooke JE, Menys VC, Martin MF, Davies JA. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud’s phenomenon. Eur J Clin Invest. 1985;15(1):20–3.

    PubMed  CAS  Google Scholar 

  84. Denton CP, Howell K, Stratton RJ, Black CM. Long-term low molecular weight heparin therapy for severe Raynaud’s phenomenon: a pilot study. Clin Exp Rheumatol. 2000;18(4):499–502.

    PubMed  CAS  Google Scholar 

  85. Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N. Effect of the dual endothelin receptor antagonist bosentan on Raynaud’s phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford). 2010;49(3):583–7. doi:10.1093/rheumatology/kep413.

    CAS  Google Scholar 

  86. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol. 2008;35:1801–8.

    PubMed  CAS  Google Scholar 

  87. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblended trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006;25(2):205–12.

    PubMed  CAS  Google Scholar 

  88. Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud’s phenomenon: a literature review and meta-analysis. Rheumatology (Oxford). 2009;48(7):791–5. doi:10.1093/rheumatology/kep039. Review, PMID: 1943343.

    Google Scholar 

  89. Muir AH, Robb R, McLaren M, Daly F, Belch JJ. The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo controlled trial. Vasc Med. 2002;7(4):265–7.

    PubMed  Google Scholar 

  90. Choi WS, Choi CJ, Kim KS, Lee JH, Song CH, Chung JH, Ock SM, Lee JB, Kim CM. To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud’s phenomenon in South Korea; Korean Raynaud study (KOARA study). Clin Rheumatol. 2009;28(5):553–9. doi:10.1007/s10067-008-1084-9.

    PubMed  Google Scholar 

  91. Denton CP, Bunce TD, Dorado MB, Roberts Z, Wilson H, Howell K, Bruckdorfer KR, Black CM. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology (Oxford). 1999;38(4):309–15.

    CAS  Google Scholar 

  92. Mavrikakis ME, Lekakis JP, Papamichael CM, Stamatelopoulos KS, Kostopoulos CC, Stamatelopoulos SF. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud’s phenomenon secondary to systemic sclerosis. Int J Vitam Nutr Res. 2003;73(1):3–7.

    PubMed  CAS  Google Scholar 

  93. DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud’s phenomenon: a double-blind, controlled, prospective study. Am J Med. 1989;86(2):158–64.

    PubMed  CAS  Google Scholar 

  94. Malenfant D, Summers K, Seney S, McBain D, Petrlich L, Watson S, Vanderhoek L, Samadi N, Bonner A, Pope J. Results of a pilot randomized placebo-controlled trial in primary and secondary Raynaud’s phenomenon with St John’s Wort: detecting changes in angiogenic cytokines when RP improves. ISRN Rheumatol. 2011;2011:580704. doi:10.5402/2011/580704. PMID:22389797.

    PubMed  PubMed Central  Google Scholar 

  95. Sporbeck B, Mathiske-Schmidt K, Jahr S, Huscher D, Becker M, Riemekasten G, Taufmann I, Burmester GR, Pögel S, Reisshauer A. Effect of biofeedback and deep oscillation on Raynaud’s phenomenon secondary to systemic sclerosis: results of a controlled prospective randomized clinical trial. Rheumatol Int. 2012;32(5):1469–73. doi:10.1007/s00296-011-1882-2.

    PubMed  Google Scholar 

  96. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med. 2000;160(8):1101–8.

    Google Scholar 

  97. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A. Cyclofenil for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;(2):CD000955. Review. PMID: 10796397.

    Google Scholar 

  98. Jayson MI, Holland CD, Keegan A, Illingworth K, Taylor L. A controlled study of stanozolol in primary Raynaud’s phenomenon and systemic sclerosis. Ann Rheum Dis. 1991;50(1):41–7.

    PubMed  CAS  PubMed Central  Google Scholar 

  99. Dessein PH, Morrison RC, Lamparelli RD, van der Merwe CA. Triiodothyronine treatment for Raynaud’s phenomenon: a controlled trial. J Rheumatol. 1990;17(8):1025–8.

    PubMed  CAS  Google Scholar 

  100. Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H, Kambayashi J, Orlandi C, Czerwiec FS. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum. 2004;50(12):3994–4001.

    PubMed  CAS  Google Scholar 

  101. Herrick AL, Murray AK, Ruck A, Rouru J, Moore TL, Whiteside J, Hakulinen P, Wigley F, Snapir A.A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. Rheumatology (Oxford). 2014;53(5):948–52.

    CAS  Google Scholar 

  102. Dompeling EC, Smit AJ. Assessment of pinacidil in patients with primary Raynaud’s phenomenon. Vasa Suppl. 1992;34:34–7.

    PubMed  CAS  Google Scholar 

  103. Fava A, Wung PK, Wigley FM, Hummers LK, Daya NR, Ghazarian SR, Boin F. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud’s phenomenon. Arthritis Care Res (Hoboken). 2012;64(6):925–9. doi:10.1002/acr.21622.

    CAS  Google Scholar 

  104. Ghofrani H-A, Galiè N, Grimminger F, Grűnig E, Humbert M, Jing Z-C, et al. Riociguat for the treatment of pulmonary arterial hypertension. NEJM. 2013;369:330–40.

    PubMed  CAS  Google Scholar 

  105. Hayoz D, Bizzini G, Noël B, Depairon M, Burnier M, Fauveau C, Rouillon A, Brouard R, Brunner HR. Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud’s phenomenon. Rheumatology (Oxford). 2000;39(10):1132–8.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, St. Joseph’s Health Care London, University of Western Ontario, 268 Grosvenor Street, London, ON, Canada, N6A 4V2

    Janet E. Pope M.D., M.P.H., F.R.C.P.C.

Authors
  1. Janet E. Pope M.D., M.P.H., F.R.C.P.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janet E. Pope M.D., M.P.H., F.R.C.P.C. .

Editor information

Editors and Affiliations

  1. School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

    Fredrick M. Wigley

  2. Department of Rheumatology, The University of Manchester, Manchester, United Kingdom

    Ariane L. Herrick

  3. Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medic, Baltimore, Maryland, USA

    Nicholas A. Flavahan

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Pope, J.E. (2015). Drug Treatment of Raynaud’s Phenomenon. In: Wigley, F., Herrick, A., Flavahan, N. (eds) Raynaud’s Phenomenon. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1526-2_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1526-2_20

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1525-5

  • Online ISBN: 978-1-4939-1526-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation